Evidence map›Paper›PMID 40452567›Full record

ArticleJournal of adolescent and young adult oncology2026

Weight-Related Outcomes Among Survivors of Adolescent and Young Adult Cancer after Anti-Obesity Medication Initiation.

Amy M Berkman, Clark R Andersen, Stephanie B Dixon, Amanda Ramirez, Katherine Gilmore, Whittney Thoman, Zayd A Razouki, David Santos, Sonali Thosani, J A Livingston and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of adolescent and young adult oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Amy M BerkmanDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID 0000-0003-0650-3664
Clark R AndersenDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Stephanie B DixonDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Amanda RamirezDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Katherine GilmoreDepartment of Cancer Survivorship, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Whittney ThomanDepartment of Cancer Survivorship, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Zayd A RazoukiDepartment of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
David SantosDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sonali ThosaniDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
J A LivingstonDepartment of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Michelle A T HildebrandtDepartment of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Michael E RothDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-6411-8353

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Anti-obesity medications (AOMs) have not been studied in survivors of adolescent and young adult (AYA) cancer. In this retrospective analysis, generalized additive mixed model with penalized spline described body mass index (BMI) over time among survivors of AYA cancer prescribed an AOM. Body weight and BMI at pre-AOM maximum and last follow-up were summarized, with 95% confidence intervals. Over a median follow-up time of 249 days, 63.4% of survivors had ≥5% weight reduction. The proportion of survivors with severe obesity decreased from 60% to 35%. These findings suggest that AOMs are effective for weight reduction in survivors of AYA cancer.

Indexed as

Anti-Obesity AgentsBody WeightCancer SurvivorsNeoplasmsObesityAdolescentAdultBody Mass IndexFemaleHumansMaleRetrospective StudiesYoung AdultAnti-Obesity Agentsanti-obesity medicationsobesitysurvivorship

Identifiers

PMID40452567
PMCPMC13007047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.